12.97
0.46 (3.68%)
| Previous Close | 12.51 |
| Open | 12.65 |
| Volume | 992,539 |
| Avg. Volume (3M) | 1,494,453 |
| Market Cap | 690,352,896 |
| Price / Earnings (TTM) | 12.35 |
| Price / Earnings (Forward) | 74.63 |
| Price / Sales | 2.41 |
| Price / Book | 2.31 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | 17.92% |
| Operating Margin (TTM) | -9.46% |
| Diluted EPS (TTM) | 1.12 |
| Quarterly Revenue Growth (YOY) | 17.50% |
| Total Debt/Equity (MRQ) | 7.98% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 26.78 M |
| Levered Free Cash Flow (TTM) | 29.89 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | 19.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | CareDx, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 3.22% |
| % Held by Institutions | 99.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 26.00 (Craig-Hallum, 100.46%) | Buy |
| Median | 22.00 (69.62%) | |
| Low | 14.00 (Wells Fargo, 7.94%) | Hold |
| Average | 20.67 (59.37%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 12.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 12 Sep 2025 | 22.00 (69.62%) | Buy | 13.53 |
| Wells Fargo | 08 Aug 2025 | 14.00 (7.94%) | Hold | 11.97 |
| Craig-Hallum | 18 Jul 2025 | 26.00 (100.46%) | Buy | 11.92 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BICKERSTAFF GEORGE | - | - | 0 | 0 |
| KENNEDY KEITH | - | 13.53 | -7,987 | -108,064 |
| MENG JESSICA | - | 13.53 | -4,703 | -63,632 |
| Aggregate Net Quantity | -12,690 | |||
| Aggregate Net Value ($) | -171,696 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.53 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KENNEDY KEITH | Officer | 12 Sep 2025 | Disposed (-) | 7,987 | 13.53 | 108,064 |
| MENG JESSICA | Officer | 12 Sep 2025 | Disposed (-) | 4,703 | 13.53 | 63,632 |
| BICKERSTAFF GEORGE | Director | 11 Sep 2025 | Option execute | 29,136 | - | - |
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | CareDx Issues Comment Letter on Draft LCD Policy |
| 21 Aug 2025 | Announcement | CareDx to Participate in Wells Fargo Healthcare Conference |
| 06 Aug 2025 | Announcement | CareDx Announces Appointment of Nathan Smith as Chief Financial Officer |
| 06 Aug 2025 | Announcement | CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation |
| 31 Jul 2025 | Announcement | CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress |
| 23 Jul 2025 | Announcement | CareDx to Report Second Quarter 2025 Financial Results |
| 18 Jul 2025 | Announcement | CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |